Overview

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Status:
Unknown status

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare chemotherapy and gefitinib in combination with gefitinib alone as first-line therapy for adenocarcinoma, in terms of efficacy and safety.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Chest Hospital

Collaborators:

Changhai Hospital
Ruijin Hospital

Treatments:

Carboplatin
Gefitinib
Pemetrexed